Research on chimeric antigen receptor-natural killer cell therapy is advancing, with studies exploring its potential in treating various diseases, including cancer and pediatric autoimmune diseases. The therapy is being investigated for its effectiveness in clinical applications, with some outlets reporting on its potential to reshape the future of cancer immunotherapy. The field appears to be progressing, with some treatments reaching phase 3 and securing significant funding, although the specific outcomes and applications of these advancements are not yet clear.